Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Terminated 2Active not recruiting 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 98pembrolizumab 87Gemcitabine 81Carboplatin 63fludarabine 62Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 50Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 34Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26atezolizumab 25Pemetrexed 25Oxaliplatin 24Capecitabine 24fludarabine phosphate 23Filgrastim 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Terminated × pelcitoclax × Clear all
NCT04893759 2025-04-17

A Study of Pelcitoclax (APG-1252) in Patients With Neuroendocrine Tumors

Ascentage Pharma Group Inc.

Phase 1 Terminated
2 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03387332 2021-08-27

APG-1252 in Patients With SCLC or Advanced Solid Tumors

Ascentage Pharma Group Inc.

Phase 1 Terminated
24 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡